Breast cancer screening: why women under 50 at high risk are being missed

In the United Kingdom, routine breast cancer screening through the NHS Breast Screening Programme typically begins at age 50, when women are invited for a mammogram every three years. That age threshold was set using population-wide statistics on when breast cancer risk climbs sharply. But a new analysis argues that the blanket cutoff leaves a significant blind spot: a substantial share of younger women who carry a personal risk well above the population average are never flagged for earlier or more frequent checks.

According to the researchers behind the analysis, up to 95% of women under 50 who fall into a higher-risk category are currently missed by the existing system. That risk can come from several sources, including a strong family history of breast or ovarian cancer, inherited mutations in genes such as BRCA1 and BRCA2, dense breast tissue that can mask tumours on a standard mammogram, or previous radiotherapy to the chest at a young age.

Risk-prediction tools already exist that combine family history, genetic test results, hormonal and reproductive factors, and breast density to estimate an individual's lifetime or ten-year risk. Several hospitals and specialist genetics clinics use these calculators to refer high-risk women for earlier or supplementary screening, such as annual mammograms starting in their thirties or forties, or breast MRI in addition to mammography.

The problem, the study's authors say, is that this kind of individualised assessment is not applied consistently. Many younger women are never referred to a risk clinic in the first place, either because their GP does not systematically ask about family history, or because there is no standard pathway for women outside the screening age bracket to be assessed proactively.

The researchers argue that closing this gap does not necessarily mean lowering the screening age for everyone. Population-wide screening for all women in their thirties and forties would sharply increase costs, false positives and unnecessary biopsies, given that overall incidence remains lower in that age group. Instead, they are calling for wider and earlier use of structured risk assessment, so that the minority of younger women who genuinely carry a high risk can be identified and monitored more closely.

Some countries already run risk-stratified programmes. In parts of the United States and continental Europe, women with a known genetic mutation or strong family history are offered annual MRI screening from as early as age 25, well ahead of general population screening. The UK has similar guidance for the highest-risk groups, but the analysis suggests that uptake and referral remain patchy across different regions and general practices.

Charities and clinicians who work with high-risk families have welcomed calls for better identification, noting that many women only discover they were eligible for earlier screening after a diagnosis, rather than before one. Improving how family history is recorded and reviewed during routine GP visits, they say, would be a low-cost way to catch more people earlier.

For readers wanting to know where they stand, the practical starting point is a conversation with a GP about family history on both the maternal and paternal side, including cases of breast, ovarian, prostate and pancreatic cancer, which can all be linked to the same inherited mutations. Online risk calculators used by the NHS and other health systems can give an initial estimate, though a formal referral to a genetics or family history clinic is needed for a full assessment.

The NHS has said it keeps its screening guidelines under regular review as evidence develops, and that women with specific concerns about their family history can ask their GP for a referral to a risk assessment service at any age, rather than waiting for an invitation letter.

The wider debate, researchers say, reflects a broader shift in cancer screening policy away from single age thresholds and toward individualised risk, a model already used in some countries for cervical and bowel cancer screening intervals. Whether that shift extends further into breast screening will depend on how health systems weigh the costs of wider risk assessment against the benefit of catching more cancers earlier in younger, higher-risk women.